Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time (CALGB 40502 and CALGB 40503, Alliance)

類似資料

• Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)
  著者:: Sharma, Manish R., 等
  出版事項: (2019)
• Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)
  著者:: Dickler, Maura N., 等
  出版事項: (2016)
• A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance)
  著者:: Rashkin, Sara R., 等
  出版事項: (2018)
• Kinetic-Pharmacodynamic Model of Chemotherapy Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel or Ixabepilone: CALGB 40502 (Alliance)
  著者:: Mehrotra, Shailly, 等
  出版事項: (2017)
• Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: A CALGB 40503 (Alliance) correlative study.
  著者:: Li, Daneng, 等
  出版事項: (2018)